High-Grade Glioma - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 118 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

High-Grade Glioma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'High-Grade Glioma - Pipeline Review, H1 2015', provides an overview of the High-Grade Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for High-Grade Glioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the High-Grade Glioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
High-Grade Glioma Overview 8
Therapeutics Development 9
Pipeline Products for High-Grade Glioma - Overview 9
Pipeline Products for High-Grade Glioma - Comparative Analysis 10
High-Grade Glioma - Therapeutics under Development by Companies 11
High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes 13
High-Grade Glioma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
High-Grade Glioma - Products under Development by Companies 16
High-Grade Glioma - Products under Investigation by Universities/Institutes 17
High-Grade Glioma - Companies Involved in Therapeutics Development 18
AngioChem Inc. 18
Bayer AG 19
Boehringer Ingelheim GmbH 20
Cavion LLC 21
GlaxoSmithKline plc 22
Kinex Pharmaceuticals, LLC 23
Millennium Pharmaceuticals, Inc. 24
Oncolytics Biotech Inc. 25
Sanofi 26
Stemline Therapeutics, Inc. 27
Targepeutics, Inc. 28
Tocagen Inc. 29
Virttu Biologics Limited 30
High-Grade Glioma - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
alisertib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ANG-1005 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
crenolanib besylate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dendritic Cell Therapy for Gliomas - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Dendritic Cell Therapy for Oncology - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GB-13 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HSV-1716 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
KX-02 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
mibefradil dihydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
nintedanib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pelareorep - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
plerixafor - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SL-701 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
sorafenib tosylate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Stem Cell Therapy for Glioma - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TBX-01 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Toca-Gamma - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Toca-RNAi - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
High-Grade Glioma - Recent Pipeline Updates 85
High-Grade Glioma - Dormant Projects 115
High-Grade Glioma - Discontinued Products 116
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 117
Disclaimer 118

List of Tables

Number of Products under Development for High-Grade Glioma, H1 2015 9
Number of Products under Development for High-Grade Glioma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
High-Grade Glioma - Pipeline by AngioChem Inc., H1 2015 18
High-Grade Glioma - Pipeline by Bayer AG, H1 2015 19
High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 20
High-Grade Glioma - Pipeline by Cavion LLC, H1 2015 21
High-Grade Glioma - Pipeline by GlaxoSmithKline plc, H1 2015 22
High-Grade Glioma - Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 23
High-Grade Glioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 24
High-Grade Glioma - Pipeline by Oncolytics Biotech Inc., H1 2015 25
High-Grade Glioma - Pipeline by Sanofi, H1 2015 26
High-Grade Glioma - Pipeline by Stemline Therapeutics, Inc., H1 2015 27
High-Grade Glioma - Pipeline by Targepeutics, Inc., H1 2015 28
High-Grade Glioma - Pipeline by Tocagen Inc., H1 2015 29
High-Grade Glioma - Pipeline by Virttu Biologics Limited, H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Assessment by Combination Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
High-Grade Glioma Therapeutics - Recent Pipeline Updates, H1 2015 85
High-Grade Glioma - Dormant Projects, H1 2015 115
High-Grade Glioma - Discontinued Products, H1 2015 116